Newsweek on MSN1h
Amgen Drug Delivers More Weight Loss Than CompetitorsA new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...
Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...
Wall Street analysts did not think the data showed enough differentiation.
RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...
That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...
showed no plateau effect in weight loss—suggesting potential for continued benefits beyond the 52-week period—these results failed to fully meet the market's elevated expectations. Fresh Amgen ...
23h
Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback